Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response (Q73011043)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007717%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

title

Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007717%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

P C van de Meeberg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007717%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

F H Wolfhagen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007717%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

G P Van Berge-Henegouwen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007717%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

J M Salemans

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007717%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

A Tangerman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007717%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

H R van Buuren

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007717%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

J van Hattum

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007717%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

K J van Erpecum

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007717%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

publication date

1 December 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007717%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007717%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007717%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007717%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

887-894

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007717%20AND%20SRC:MED&resulttype=core&format=json

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

31 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Hepatoprotection by hydrophilic bile salts

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Immunomodulating effect of ursodeoxycholic acid therapy in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Ursodeoxycholate-induced hypercholeresis in cirrhotic rats: further evidence for cholehepatic shunting

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by the SeHCAT test

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Bioavailability, gastrointestinal transit, solubilization and faecal excretion of ursodeoxycholic acid in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Ileal excretion of bile acids: Comparison with biliary bile composition and effect of ursodeoxycholic acid treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Intestinal absorption of ursodeoxycholic acid in patients with extrahepatic biliary obstruction and bile drainage

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Pharmacology of ursodeoxycholic acid, an enterohepatic drug.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Ursodeoxycholic acid therapy and biliary lipids--a dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Differing effects of ursodeoxycholic or chenodeoxycholic acid on biliary cholesterol saturation and bile acid metabolism in man. A dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Effect of different doses of ursodeoxycholic acid in chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Active absorption of conjugated bile acids in vivo. Kinetic parameters and molecular specificity of the ileal transport system in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Lipoproteins and liposomes as in vivo cholesterol vehicles in the rat: preferential use of cholesterol carried by small unilamellar liposomes for the formation of muricholic acids

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Serum bile acid analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Effect of ageing on postprandial conjugated and unconjugated serum bile acid levels in healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Analysis of conjugated and unconjugated bile acids in serum and jejunal fluid of normal subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Sulphated and unsulphated bile acids in serum, bile, and urine of patients with cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Characterisation of patients with a complete biochemical response to ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980293-5

7 January 2021

10.1016/S0168-8278(96)80293-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007717%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference